GlassScriptPhysician profile
David M Yamada
NPI 1932152329
$4,980.99
in general payments reported to CMS, 2019-2025
31 companies · $762 in 2025
The $762 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,109 · 2020: $322 · 2021: $517 · 2022: $847 · 2023: $646 · 2024: $778 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,186.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $894.61 | 2019-2025 | |
| Pfizer INC. | $714.26 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $550.92 | 2021-2025 | Verquvo |
| Amgen INC. | $359.82 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $337.04 | 2020-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $282.71 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $238.01 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $196.34 | 2019-2022 | |
| Biotronik INC. | $155.66 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $123.13 | 2022-2024 | Amvuttra, Onpattro |
| Kestra Medical Technology Services, INC. | $117.07 | 2022-2023 | Assure Wcd |
| Boston Scientific Corporation | $103.51 | 2021-2022 | |
| Heartflow, INC. | $98.52 | 2024-2025 | |
| Philips North America LLC | $93.15 | 2025 | Diagnostic Ecg Service, Extended Holter |
| Kiniksa Pharmaceuticals International, Plc | $80.07 | 2024 | Arcalyst |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $78.73 | 2019 | |
| Cvrx, INC. | $75.80 | 2022-2024 | Barostim Neo System |
| Amarin Pharma, INC. | $65.51 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.19 | 2019-2022 | |
| Abbott Laboratories | $55.43 | 2019-2024 | Aveir |
| Kiniksa Pharmaceuticals, LTD. | $52.75 | 2021-2023 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $41.48 | 2021-2022 | |
| Acutus Medical, INC. | $40.07 | 2022 | |
| Novo Nordisk INC | $31.47 | 2021-2024 | Ozempic, Rybelsus |
| Medtronic, INC. | $24.84 | 2023 | Linq II |
| Astellas Pharma US INC | $22.93 | 2023 | Veozah |
| Biosense Webster, INC. | $19.70 | 2025 | Nuvision Ice Catheter |
| Scpharmaceuticals INC. | $17.17 | 2024 | |
| Abiomed | $16.61 | 2023 | Impella |
| Cardiovascular Systems INC. | $16.51 | 2020 | |
| Sobi, INC | $13.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Yamada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.